Sun Jia Teng, Chen Zhongli, Nie Peng, Ge Heng, Shen Long, Yang Fan, Qu Xiao Long, Ying Xiao Ying, Zhou Yong, Wang Wei, Zhang Min, Pu Jun
Division of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Division of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, China.
Front Cardiovasc Med. 2020 Dec 4;7:584987. doi: 10.3389/fcvm.2020.584987. eCollection 2020.
Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality. We conducted a prospective observational cohort study to investigate lipid profile features in patients with COVID-19. From 9 February to 4 April 2020, a total of 99 patients (31 critically ill and 20 severely ill) with confirmed COVID-19 were included in the study. Dynamic alterations in lipid profiles were recorded and tracked. Outcomes were followed up until 4 April 2020. We found that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-1 (apoA-1) levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels ( < 0.0001). Furthermore, HDL-C and apoA-1 levels were independently associated with disease severity (apoA-1: odds ratio (OR): 0.651, 95% confidence interval (CI): 0.456-0.929, = 0.018; HDL-C: OR: 0.643, 95% CI: 0.456-0.906, = 0.012). For predicting disease severity, the areas under the receiver operating characteristic curves (AUCs) of HDL-C and apoA-1 levels at admission were 0.78 (95% CI, 0.70-0.85) and 0.85 (95% CI, 0.76-0.91), respectively. For in-hospital deaths, HDL-C and apoA-1 levels demonstrated similar discrimination ability, with AUCs of 0.75 (95% CI, 0.61-0.88) and 0.74 (95% CI, 0.61-0.88), respectively. Moreover, patients with lower serum concentrations of apoA-1 (<0.95 g/L) or HDL-C (<0.84 mmol/l) had higher mortality rates during hospitalization (log-rank < 0.001). Notably, levels of apoA-1 and HDL-C were inversely proportional to disease severity. The survivors of severe cases showed significant recovery of apoA-1 levels at the end of hospitalization (vs. midterm apoA-1 levels, = 0.02), whereas the mortality cases demonstrated continuously lower apoA-1 levels throughout hospitalization. Correlation analysis revealed that apoA-1 and HDL-C levels were negatively correlated with both admission levels and highest concentrations of C-reactive protein and interleukin-6. Severely ill COVID-19 patients featured low HDL-C and apoA-1 levels, which were strongly correlated with inflammatory states. Thus, low apoA-1 and HDL-C levels may be promising predictors for severe disease and in-hospital mortality in patients suffering from COVID-19.
新兴研究已经描述并分析了新型冠状病毒肺炎(COVID-19)患者的流行病学、临床、实验室及影像学特征。然而,关于血脂谱特征与疾病严重程度及死亡率之间的关联,现有信息却很匮乏。我们开展了一项前瞻性观察性队列研究,以调查COVID-19患者的血脂谱特征。2020年2月9日至4月4日,共有99例确诊COVID-19的患者(31例危重症患者和20例重症患者)纳入本研究。记录并跟踪血脂谱的动态变化。随访结局至2020年4月4日。我们发现,重症组的高密度脂蛋白胆固醇(HDL-C)和载脂蛋白A-1(apoA-1)水平显著降低,死亡病例的水平最低(<0.0001)。此外,HDL-C和apoA-1水平与疾病严重程度独立相关(apoA-1:比值比(OR):0.651,95%置信区间(CI):0.456 - 0.929,P = 0.018;HDL-C:OR:0.643,95% CI:0.456 - 0.906,P = 0.012)。对于预测疾病严重程度,入院时HDL-C和apoA-1水平的受试者工作特征曲线下面积(AUC)分别为0.78(95% CI,0.70 - 0.